Recruiting at 2 sites No phase Restless Leg Syndrome (RLS)

Restless Leg Syndrome study: Cannabis oil

Official title Using Cannabis to Treat Restless Legs Syndrome

ClinicalTrials.gov ID: NCT06863740

What this study is testing

What is MPL-005?

an investigational oral cannabis oil being studied as a potential treatment for Restless Leg Syndrome (RLS)

Also referred to as Cannabis oil.

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The study wants to see if cannabis is safe and practical to use for restless legs syndrome and whether it affects sleep quality and overall well‑being.
Who it's for
Adults who have moderate‑to‑severe restless legs syndrome.
What's involved
Participants will be randomly assigned to take either cannabis or a placebo for 8 weeks, with sleep and quality‑of‑life questionnaires and safety checks at the start and end.
Time commitment
The trial lasts 8 weeks and includes visits at the beginning and after the 8‑week period for assessments.
  • You might receive a placebo (an inactive treatment) instead of the study drug.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 25 and older

You may be able to join if

  • ≥25 years of age
  • diagnosis of RLS based on the International RLS Study Group criteria
  • refractory RLS symptoms despite use of dopaminergic and/or alpha-2-delta ligand therapy
  • onset of RLS at least 6 months before screening

You likely can't join if

  • sleep disordered breathing, or sleep disordered breathing that is not adequately controlled on therapy (apnea-hypopnea index of \>15)
  • cannabis use within 4 weeks of study enrollment
  • known allergy to cannabis, cannabinoids or palm/coconut oil
  • Currently pregnant or breast-feeding (a negative urine pregnancy test must be obtained for women of childbearing potential during pretreatment...
  • Active substance abuse
  • Ischemic heart disease with unstable angina or recent acute coronary syndrome in the last 3 months, uncontrolled arrhythmias, poorly controlled...
See the full eligibility criteria
Who can join
  • ≥25 years of age
  • diagnosis of RLS based on the International RLS Study Group criteria
  • refractory RLS symptoms despite use of dopaminergic and/or alpha-2-delta ligand therapy
  • onset of RLS at least 6 months before screening
What rules you out
  • sleep disordered breathing, or sleep disordered breathing that is not adequately controlled on therapy (apnea-hypopnea index of \>15)
  • cannabis use within 4 weeks of study enrollment
  • known allergy to cannabis, cannabinoids or palm/coconut oil
  • Currently pregnant or breast-feeding (a negative urine pregnancy test must be obtained for women of childbearing potential during pretreatment evaluation)
  • Active substance abuse
  • Ischemic heart disease with unstable angina or recent acute coronary syndrome in the last 3 months, uncontrolled arrhythmias, poorly controlled hypertension
  • Serious liver disease
  • History of schizophrenia or any other psychotic disorder

The study team makes the final eligibility decision.

Where it is enrolling

  • Toronto, Ontario, Canada

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 25 years and older. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Toronto, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.